Transplant Research Center, Chiara Cucchi De Alessandri & Gilberto Crespi Mario Negri Institute for Pharmacological Research, Via Camozzi, Bergamo, Italy.
Transplantation. 2011 Aug 15;92(3):271-9. doi: 10.1097/TP.0b013e3182241106.
Ischemia/reperfusion (I/R) injury is an important cause of renal graft dysfunction. Increases in cold and warm ischemia times lead to a higher risk of early posttransplant complications including delayed graft function and acute rejection. Moreover, prolonged cold ischemia is a predictor of long-term graft loss in kidney transplant patients.
Darbepoetin alfa (DA) and carbamylated nonerythropoietic derivative of erythropoietin (CEPO) protective effects were evaluated in a model of I/R injury after kidney transplantation in both syngeneic and allogeneic combinations. The effects of wortmannin (phosphorylated Akt [p-Akt] inhibitor) administration were also investigated. Serum creatinine was evaluated at 16, 24, 48 hr and at 4 and 7 days posttransplant. Animals were killed 24 hr or 7 days after transplant and kidneys were processed for histological analysis, immunohistochemistry assessment of erythropoietin receptor (EPOR) and β-common chain receptor expression, granulocyte infiltration, nitrotyrosine staining, p-Akt expression, peritubular capillary (PTC) density, apoptosis, antioxidant, and antiapoptotic gene expression.
DA and CEPO significantly reduced serum creatinine, tubular injury, tubular nitrotyrosine staining, and prevented I/R-induced tubular apoptosis, but only when given both to the donor and to the recipient. DA and CEPO cytoprotection was associated with prevention of I/R-induced drop of p-Akt expression in tubuli, and almost complete preservation of capillary density in the tubulointerstitium of the graft. CEPO was more effective than DA in reducing tubular oxidative stress and preserving PTCs.
DA and CEPO when given both to the donor and to the recipient, prevented renal graft dysfunction, tubular oxidative stress, and apoptosis after I/R injury in kidney transplantation. Their cytoprotection was mediated by tubular p-Akt activation and PTC density preservation.
缺血/再灌注(I/R)损伤是肾移植功能障碍的一个重要原因。冷缺血和热缺血时间的增加会导致更高的早期移植后并发症风险,包括移植肾功能延迟恢复和急性排斥反应。此外,长时间的冷缺血是肾移植患者发生长期移植物丢失的一个预测因素。
在肾移植后 I/R 损伤模型中,评估了达贝泊汀(DA)和氨甲酰基非红细胞生成素衍生的促红细胞生成素(CEPO)的保护作用,包括在同基因和同种异体组合中。还研究了wortmannin(磷酸化 Akt [p-Akt]抑制剂)给药的效果。在移植后 16、24、48 小时和 4、7 天评估血清肌酐。在移植后 24 小时或 7 天处死动物,并对肾脏进行组织学分析、促红细胞生成素受体(EPOR)和β-共同链受体表达的免疫组化评估、粒细胞浸润、硝基酪氨酸染色、p-Akt 表达、肾小管周毛细血管(PTC)密度、细胞凋亡、抗氧化和抗凋亡基因表达。
DA 和 CEPO 显著降低了血清肌酐、肾小管损伤、肾小管硝基酪氨酸染色,并预防了 I/R 诱导的肾小管凋亡,但只有在供体和受体都给予 DA 和 CEPO 时才会出现这种情况。DA 和 CEPO 的细胞保护作用与预防 I/R 诱导的小管 p-Akt 表达下降有关,并且几乎完全保留了移植物肾小管间质中的毛细血管密度。CEPO 在降低肾小管氧化应激和保护 PTC 方面比 DA 更有效。
DA 和 CEPO 同时给予供体和受体,可预防肾移植后 I/R 损伤引起的肾功能障碍、肾小管氧化应激和细胞凋亡。它们的细胞保护作用是通过小管 p-Akt 激活和 PTC 密度的维持介导的。